未知生产厂商
Pozelimab is a human monoclonal IgG4 antibody used to treat CD55-deficient protein-losing enteropathy (PLE) or CHAPLE disease
Pozelimab is a human monoclonal IgG4 antibody used to treat CD55-deficient protein-losing enteropathy (PLE) or CHAPLE disease
Pozelimab-bbfg is a human, monoclonal immunoglobulin G4P (IgG4) antibody directed against the terminal complement protein C5 that inhibits terminal complement activation by blocking cleavage of C5 into C5a (anaphylatoxin) and C5b, thereby blocking the formation of the membrane-attack complex (C5b-C9, a structure mediating cell lysis).
Pozelimab is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
